187 related articles for article (PubMed ID: 14642684)
1. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
Sidhu JS; Cowan D; Kaski JC
J Am Coll Cardiol; 2003 Nov; 42(10):1757-63. PubMed ID: 14642684
[TBL] [Abstract][Full Text] [Related]
2. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.
Sidhu JS; Cowan D; Kaski JC
Am J Cardiol; 2004 Jul; 94(2):151-6. PubMed ID: 15246889
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.
Sidhu JS; Kaposzta Z; Markus HS; Kaski JC
Arterioscler Thromb Vasc Biol; 2004 May; 24(5):930-4. PubMed ID: 15001452
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease.
Sidhu JS; Cowan D; Tooze JA; Kaski JC
Am Heart J; 2004 Jun; 147(6):e25. PubMed ID: 15199366
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.
Marx N; Imhof A; Froehlich J; Siam L; Ittner J; Wierse G; Schmidt A; Maerz W; Hombach V; Koenig W
Circulation; 2003 Apr; 107(15):1954-7. PubMed ID: 12695287
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
Gee MK; Zhang L; Rankin SE; Collins JN; Kauffman RF; Wagner JD
Metabolism; 2004 Sep; 53(9):1121-5. PubMed ID: 15334371
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone reduces plasma levels of inflammatory and hemostatic biomarkers and improves global endothelial function in habitual heavy smokers without diabetes mellitus or metabolic syndrome.
Chen IC; Chao TH; Tsai WC; Li YH
J Formos Med Assoc; 2010 Feb; 109(2):113-9. PubMed ID: 20206835
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X
Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
[TBL] [Abstract][Full Text] [Related]
10. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.
Marx N; Froehlich J; Siam L; Ittner J; Wierse G; Schmidt A; Scharnagl H; Hombach V; Koenig W
Arterioscler Thromb Vasc Biol; 2003 Feb; 23(2):283-8. PubMed ID: 12588772
[TBL] [Abstract][Full Text] [Related]
11. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
Yang WS; Jeng CY; Wu TJ; Tanaka S; Funahashi T; Matsuzawa Y; Wang JP; Chen CL; Tai TY; Chuang LM
Diabetes Care; 2002 Feb; 25(2):376-80. PubMed ID: 11815513
[TBL] [Abstract][Full Text] [Related]
12. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Haffner SM; Greenberg AS; Weston WM; Chen H; Williams K; Freed MI
Circulation; 2002 Aug; 106(6):679-84. PubMed ID: 12163427
[TBL] [Abstract][Full Text] [Related]
13. [Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome].
Bahia L; Aguiar LG; Villela N; Bottino D; Godoy-Matos AF; Bouskela E
Arq Bras Cardiol; 2006 May; 86(5):366-73. PubMed ID: 16751941
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease.
Yu J; Zhang Z; Li Z; Feng X; He L; Liu S; Mao J; Wang G; Wang X
J Int Med Res; 2010; 38(1):86-94. PubMed ID: 20233517
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation.
Cuzzocrea S; Pisano B; Dugo L; Ianaro A; Maffia P; Patel NS; Di Paola R; Ialenti A; Genovese T; Chatterjee PK; Di Rosa M; Caputi AP; Thiemermann C
Eur J Pharmacol; 2004 Jan; 483(1):79-93. PubMed ID: 14709329
[TBL] [Abstract][Full Text] [Related]
16. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.
Wang TD; Chen WJ; Cheng WC; Lin JW; Chen MF; Lee YT
Am J Cardiol; 2006 Oct; 98(8):1057-62. PubMed ID: 17027571
[TBL] [Abstract][Full Text] [Related]
17. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.
Hadigan C; Yawetz S; Thomas A; Havers F; Sax PE; Grinspoon S
Ann Intern Med; 2004 May; 140(10):786-94. PubMed ID: 15148065
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.
Levi Z; Shaish A; Yacov N; Levkovitz H; Trestman S; Gerber Y; Cohen H; Dvir A; Rhachmani R; Ravid M; Harats D
Diabetes Obes Metab; 2003 Jan; 5(1):45-50. PubMed ID: 12542724
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease.
Staniloae C; Mandadi V; Kurian D; Coppola J; Bernaski E; El-Khally Z; Morlote M; Pinassi E; Ambrose J
Cardiology; 2007; 108(3):164-9. PubMed ID: 17077630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
